NCT07216703View on ClinicalTrials.gov

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,023

Participants

Timeline

Start Date

November 18, 2025

Primary Completion Date

October 29, 2031

Study Completion Date

October 29, 2031

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

Pembrolizumab

Intravenous (IV) Infusion

BIOLOGICAL

Sacituzumab Tirumotecan

IV Infusion

BIOLOGICAL

Bevacizumab

IV Infusion

DRUG

Paclitaxel

IV Infusion

DRUG

Cisplatin

IV Infusion

DRUG

Carboplatin

IV Infusion

DRUG

Rescue Medications

Participants receive the following rescue medications prior to sac-TMT infusion, per approved product label: histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY